Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3164512 | 0.85 | FAAH (0.41) | FAAHMEN1KMT2AMCL1ALDH1A1 | |
| SCHEMBL3165433 | 0.85 | ALDH1A1 (0.42) | FAAHMEN1KMT2AMCL1ALDH1A1 | |
| SCHEMBL3267160 | 0.83 | FAAH (0.38) | FAAHMEN1KMT2AMCL1ALDH1A1 | |
| SCHEMBL3162673 | 0.83 | FAAH (0.46) | FAAHMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL27856260 | 0.83 | HTR1A (0.42) | FAAHMEN1KMT2AMCL1ALDH1A1 | |
| SCHEMBL690572 | 0.82 | RORC (0.40) | FAAHMEN1KMT2AMCL1ALDH1A1 | |
| SCHEMBL692867 | 0.81 | LMNA (0.44) | MCL1ALDH1A1KDM4ECMA1LMNA | |
| SCHEMBL690228 | 0.81 | EPHX2 (0.42) | FAAHMEN1KMT2AMCL1ALDH1A1 | |
| SCHEMBL689275 | 0.81 | EPHX2 (0.42) | FAAHMEN1KMT2AMCL1ALDH1A1 | |
| SCHEMBL3228834 | 0.81 | EPHX2 (0.42) | FAAHMEN1KMT2AMCL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786801-B1 | 2-ARYLCARBAMOYL-INDOLES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2010-03-10 | — | — | EP | disclosed |
| US-7470692-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20060046986-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046986-A1 | Cytokine inhibitors | IL1B, TNF, IL1A | FAAH 2417/4885MEN1 4481/4885KMT2A 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.